Clinical trials: Bullous Dermatoses
Pemphigoid, Bullous
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
Randomized, placebo-controlled, double-blind study evaluating the effect of anti-IL-5-therapy in patients with bullous pemphigoid.
- Trial name
- NCT01705795
- Testing
- Mepolizumab (a-IL-5 antibody)
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pemphigoid, Pruritus
Pruritus and Pemphigoid in Nursing Home Patients
The primary objective of this observational study is to describe the prevalence of pruritus and pemphigoid in nursing home patients.
- Trial name
- SSENIOR (NCT02823067)
- Testing
- Blood sample
- Where
- Netherlands
- Volunteers
- 125 people
- Sponsor
- M.F. Jonkman
Pemphigoid, Bullous
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).
- Trial name
- NCT04499235
- Testing
- Mometasone furoate, AKST4290
- Where
- 8 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Alkahest, Inc.
Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects…
- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
- Trial name
- NCT07011589
- Testing
- Efgartigimod
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M. Peter Marinkovich